Select Medical Holdings Corporation Announces Results For Its First Quarter Ended March 31, 2025 and Cash Dividend

Core Viewpoint - Select Medical Holdings Corporation reported a 2.4% increase in revenue for Q1 2025, alongside a significant rise in net income from continuing operations, indicating a positive financial trajectory despite challenges in certain segments [2][12]. Financial Performance - Revenue for Q1 2025 reached $1,353.2 million, up from $1,321.2 million in Q1 2024 [2]. - Income from continuing operations before other income and expense was $112.7 million, a decrease from $118.5 million year-over-year [2]. - Net income from continuing operations increased by 21.5% to $74.7 million compared to $61.5 million in the prior year [2]. - Adjusted EBITDA for Q1 2025 was $151.4 million, down from $165.8 million in Q1 2024 [2]. - Earnings per share from continuing operations rose by 33.3% to $0.44, compared to $0.33 in the same quarter last year [2]. Segment Performance - Critical Illness Recovery Hospital Segment: Revenue decreased by 2.9% to $637.0 million, with Adjusted EBITDA down 25.3% to $86.6 million [5][23]. - Rehabilitation Hospital Segment: Revenue increased by 15.7% to $307.4 million, with Adjusted EBITDA rising by 14.7% to $70.4 million [6][23]. - Outpatient Rehabilitation Segment: Revenue increased by 1.4% to $307.3 million, while Adjusted EBITDA slightly decreased to $24.3 million [7][24]. Company Overview - Select Medical operates 104 critical illness recovery hospitals, 35 rehabilitation hospitals, and 1,911 outpatient rehabilitation clinics across 40 states and the District of Columbia as of March 31, 2025 [4]. Dividend and Stock Repurchase - The Board of Directors declared a cash dividend of $0.0625 per share, payable on or about May 29, 2025 [8]. - A stock repurchase program was authorized for up to $1.0 billion, with 649,804 shares repurchased at a cost of approximately $11.4 million during Q1 2025 [10][11]. Business Outlook - For fiscal year 2025, Select Medical expects revenue between $5.3 billion and $5.5 billion, Adjusted EBITDA between $510 million and $530 million, and fully diluted earnings per share between $1.09 and $1.19 [12].